Log on / register
Feedback | Support | My details
Open AccessResearch article

The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study

Scott R Berry1,2 email, Stacey Hubay3 email, Hagit Soibelman4 email and Douglas K Martin2,5 email

Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, Canada

University of Toronto Joint Centre for Bioethics, Toronto, Canada

Grand River Regional Cancer Centre, Division of Medical Oncology, Kitchener, Ontario, Canada

Student, Faculty of Nursing, University of Toronto, Toronto, Canada

Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

author email corresponding author email

BMC Health Services Research 2007, 7:193doi:10.1186/1472-6963-7-193

Published: 28 November 2007

Abstract

Background

Health care policies, including drug-funding policies, influence physician practice. Funding policies are especially important in the area of cancer care since cancer is a leading cause of death that is responsible for a significant level of health care expenditures. Recognizing the rising cost of cancer therapies, Cancer Care Ontario (CCO) established a funding process to provide access to new, effective agents through a "New Drug Funding Program" (NDFP). The purpose of this study is to describe oncologists' perceptions of the impact of NDFP priority setting decisions on their practice.

Methods

This is a qualitative study involving semi-structured, in-depth interviews with 46 medical oncologists in Ontario. Oncologists were asked to describe the impact of CCO's NDFP drug funding decisions on their practice. Analysis of interview transcripts commenced with data collection.

Results

Our key finding is that many of the medical oncologists who participated in this study did not accept limits when policy decisions limit access to cancer drugs they feel would benefit their patients. Moreover, overcoming those limits had a significant impact on oncologists' practice in terms of how they spend their time and energy and their relationship with patients.

Conclusion

When priority setting decisions limit access to cancer medications, many oncologists' efforts to overcome those limits have a significant impact on their practice. Policy makers need to seriously consider the implications of their decisions on physicians, who may go to considerable effort to circumvent their policies in the name of patient advocacy.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.